- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Obamacare Question: Ditch Employer Mandate?
A left-leaning think tank whose research is often taken seriously by backers of the health-care overhaul has published a paper suggesting the administration should scrap the health law's requirement that employers offer coverage or pay a penalty.
A left-leaning think tank whose research is often taken seriously by backers of the health-care overhaul has published a paper suggesting the administration should scrap the health law’s requirement that employers offer coverage or pay a penalty.
“Why Don’t We Just Get Rid of the Employer Mandate?”, by three researchers at the Urban Institute, argues that the requirement won’t lead to many more people gaining coverage, since most firms that don’t currently offer benefits to all their workers will opt for the penalty, and most firms that already voluntarily offer benefits will want to carry on doing so.
The researchers say that the penalty isn’t necessary to stop employers from dumping their workers now that they can get coverage other ways. They reason that workers will still consider employer insurance attractive, and so employers will conclude that it’s worth providing because tax breaks on employee benefits offset some of the cost of providing them.
Read the full story here: http://on.wsj.com/1nEQHRe
Source: The Wall Street Journal
Hospital Participation in Medicare ACOs: No Change in Admission Practices and Spending
August 19th 2025Hospital accountable care organization (ACO) participation did not impact emergency department admission rates, length of stay, or costs, suggesting limited effectiveness in reducing spending for unplanned admissions and challenging hospital-led ACO cost-saving strategies.
Read More
Roflumilast Cream 0.05% Durable, Safe for Younger Pediatric Patients
August 15th 2025The INTEGUMENT-OLE study is an open-label extension analysis that followed a primary investigation from the phase 3 INTEGUMENT-PED trial, which investigated the efficacy and safety of once-daily roflumilast cream 0.05% for atopic dermatitis in children aged 2 to 5 years.
Read More
